In vivo disintegration profile of encapsulated and nonencapsulated sumatriptan: Gamma scintigraphy in healthy volunteers

Journal of Clinical Pharmacology

Volumn 45, Issue 1, 2005, Pages 101-105

  Wilding, Ian R ^a   Clark, Darren ^a   Wray, Heather ^a   Alderman, Jeff ^b   Muirhead, Nancy ^b   Sikes, Carolyn R ^b  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Bioequivalence; Disintegration; Encapsulation; Gamma scintigraphy; Sumatriptan

Indexed keywords

INDIUM 111; SUMATRIPTAN; TECHNETIUM 99M;

ADULT; ARTICLE; BIOEQUIVALENCE; CROSSOVER PROCEDURE; DRUG CAPSULE; DRUG SOLUBILITY; ENCAPSULATION; FEMALE; GAMMA SCINTIGRAPHY; GEL; HUMAN; ISOTOPE LABELING; MALE; MIGRAINE; NORMAL HUMAN; PILOT STUDY; SCINTILLATION CAMERA; SEROTONINERGIC SYSTEM; TABLET FORMULATION; BIOAVAILABILITY; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL TRANSIT; METABOLISM; METHODOLOGY; MICROCAPSULE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING; SOLUBILITY;

ADULT; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FEMALE; GAMMA CAMERAS; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RADIONUCLIDE IMAGING; SOLUBILITY; SUMATRIPTAN;

EID: 16644363277     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004270560     Document Type: Article

References (25)

1. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology. 2000;54:156-163.
2. Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology. 2002;59:1210-1217.
3. Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes C. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache. 2003;43:214-222.
4. International Headache Society Clinical Trials Subcommittee. Clinical trials guidelines for controlled trials of drugs in migraine. Cephalalgia. 2000;20:765-786.
5. Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology. Vol. 3. New York: Marcel Dekker; 1990.
6. Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol. 1991;31:314-322.
7. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol. 1996;53:1132-1137.
8. Sikes C, Alderman J, Emir B, Wilding I. Encapsulation of sumatriptan tablets does not alter their bioavailability or dissolution characteristics. Headache. 2003;43:581-582.
9. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
10. Alpsten M, Ekenved G, Solvell L. A profile scanning method of studying the release properties of different types of tablets in man. Acta Pharm Suec. 1976;13:107-122.
11. Casey DL, Beihn RM, Digenis GA, Shabhu MB. Method for monitoring hard gelatin capsule disintegration times in humans using external scintigraphy. J Pharm Sci. 1976;65:1412-1413.
12. Wilding IR, Coupe AJ, Davis SS. The role of gamma-scintigraphy in oral drug delivery. Adv Drug Deliv Rev. 2001;46:103-124.
13. Wilding IR. A scintigraphic study to evaluate what happens to Pentasa® and Asacol® in the human gut. Practical Gastroenterol. November 1999;(suppl):1-8.
14. Wilding IR, Davis SS, Steed KP, Sparrow RA, Westrup J, Hempenstall JM. Gastrointestinal transit of a drug-resinate administered as an oral suspension. Int J Pharm. 1994;101:263-268.
15. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Wilding IR. The effect of mannitol on the oral bioavailability of cimetidine. J Pharm Sci. 1995;84:1405-1409.
16. Brown J, Madit N, Cole ET, Wilding IR, Cadé D. The effect of cross-linking on the in vivo disintegration of hard gelatin capsules. Pharm Res. 1998;15:1026-1030.
17. Wilding I. Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy? J Clin Pharmacol. 2002;42:1200-1210.
18. Scott AK. Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet. 1994;27:337-344.
19. Rani PU, Naidu MUR, Kumar TR, et al. A bioequivalence study of two brands of sumatriptan. Current Ther Res. 1996;57:589-598.
20. Cutler NR, Hussey EK, Sramek JJ, et al. Pharmacokinetics of oral sumatriptan in migraine patients during an attack and while pain-free. Biol Psychiatry. 1992;31:180A.
21. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
22. Busch MA, Plachetka JR, Donn KH. Evaluation of the pharmacokinetics and safety of ascending single oral doses of GR43175 administered to healthy male volunteers. Cephalalgia. 1989;9(suppl 10):414-415.
23. Imitrex® [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2002.
24. Patten JP. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. Oral Sumatriptan Dose-Defining Study Group. J Neurol 1991;238(suppl 1):S62-S65.
25. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol. 1995;47:543-548.